v3.26.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash flows from operating activities    
Net loss $ (3,195,987) $ (6,432,840)
Adjustments to reconcile net loss to net cash used in operating activities    
Change in fair value of warrant liabilities 0 (61,194)
Stock-based compensation expense 584,439 919,119
Changes in operating assets and liabilities:    
Prepaid clinical trial costs (current and non-current) 0 328,746
Prepaid expenses and other current assets 36,251 (89,631)
Accounts payable (976,347) (1,562,387)
Accrued expenses and other current liabilities (249,652) (1,296,011)
Net cash used in operating activities (3,801,296) (8,194,198)
Cash flows from financing activities    
Repayment of short-term debt (175,601) (233,854)
Proceeds from issuance of common stock, common stock warrants, and prefunded warrants in offerings, net of transaction costs paid 9,192,991 0
Net cash provided by financing activities 11,552,735 7,271
Net increase (decrease) in cash and cash equivalents 7,751,439 (8,186,927)
Cash and cash equivalents, beginning of period 14,438,792 13,476,331
Cash and cash equivalents, end of period 22,190,231 5,289,404
Supplemental disclosures of cash flow information:    
Cash paid for taxes 675 1,075
Cash paid for interest 6,653 10,158
Noncash Investing and Financing Activities:    
Transaction costs related to offerings included in accounts payable and accrued expenses 245,202 0
Common Stock Warrants [Member]    
Cash flows from financing activities    
Proceeds from exercise of common stock warrants 8 241,125
Noncash Investing and Financing Activities:    
Issuance of warrants 5,149,950 0
Prefunded Warrants [Member]    
Noncash Investing and Financing Activities:    
Issuance of warrants 214,198 0
The Market Offering Agreement "ATM Agreement" [Member]    
Cash flows from financing activities    
Proceeds from issuance of common stock in ATM offering, net of transaction costs $ 2,535,337 $ 0